PET Scan for Men With Very Low PSA After Prostate Surgery
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a PET scan (flotufolastat F 18) to find tiny prostate cancer cells in men whose PSA is very low but still rising after prostate removal. It may help guide further treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your prostate for prostate cancer.
- Your most recent PSA level is 0.20 ng/mL or lower but not zero.
- You are not currently receiving hormone therapy for prostate cancer.
- You are at least 18 years old and male.
- You have no known allergy to the PET scan dye flotufolastat.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
This trial uses a special PET scan to detect prostate cancer when your PSA level is slightly rising after prostate removal surgery. It aims to find cancer early so treatment decisions can be better informed.
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
This study tests a newer type of PET scan (fluciclovine) in men whose previous PSMA PET scan was negative or unclear. It aims to find if the fluciclovine PET can better detect where the cancer has returned, helping guide treatment decisions.
This trial tests if a special PET scan using PSMA-1007 can find prostate cancer spread in men who have just been diagnosed with high-risk prostate cancer and plan to have surgery. The scan may help doctors better understand the cancer before removing the prostate and lymph nodes.
This trial tests a new PET scan (a type of imaging) called Flotufolastat to see if it can better monitor prostate cancer after you receive focal therapy—a treatment that targets only the cancer area rather than the whole prostate. The goal is to help doctors know if the treatment worked and catch any remaining cancer early.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.